Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • cutaneous squamous cell carcinoma

    - PMLiVE

    Regeneron’s Libtayo receives EC approval for skin cancer

    Phase 3 trial results showed the drug significantly improved disease-free survival

    regeneron headquarters

    Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma

    More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year

    regeneron headquarters

    Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

    The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

    regeneron headquarters

    Regeneron to acquire human genetics company 23andMe for $256m

    The agreement comes two months after 23andMe filed for bankruptcy protection

    - PMLiVE

    NHS programme to give melanoma patients fast-track access to skin cancer vaccine

    The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

    regeneron headquarters

    Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma

    More than 35,000 new cases of the blood cancer are diagnosed every year in Europe

    regeneron headquarters

    Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

    Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

    - PMLiVE

    Merck shares positive ten-year results for Keytruda in advanced melanoma

    More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

    regeneron headquarters

    Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study

    Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

    regeneron headquarters

    Regeneron’s odronextamab recommended by CHMP to treat certain lymphomas

    Follicular lymphoma and diffuse large B-cell lymphoma are collectively responsible for an estimated 283,000 global cases every year

    - PMLiVE

    Moderna/Merck share positive three-year results for investigational skin cancer vaccine

    More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

    regeneron headquarters

    Regeneron and Mammoth announce gene editing partnership worth $370m per target

    The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links